113 related articles for article (PubMed ID: 28592067)
1. [Combination of PP242 and dasatinib suppresses the progression of acute myeloid leukemia in a mouse model].
Qu YH; Liu HT; He FC
Zhonghua Yi Xue Za Zhi; 2017 May; 97(20):1584-1588. PubMed ID: 28592067
[No Abstract] [Full Text] [Related]
2. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
[TBL] [Abstract][Full Text] [Related]
3. [Effect of ADAR1 on the development of MLL-AF9 induced murine AML].
Peng L; Yang X; Zhang Y; Hu T; Wang W; Wang X; Xu J; Cheng T; Yuan W; Gao Y
Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):383-8. PubMed ID: 26031523
[TBL] [Abstract][Full Text] [Related]
4. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
5. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of AML Mouse Model by Transplantation of Hematopoietic Cells from MLL-AF9 Transgenic Mice].
Long WY; Shen X; Xing S; Xiong GL; Wang HG; Yu ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1369-1374. PubMed ID: 34627412
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
[TBL] [Abstract][Full Text] [Related]
8. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H
Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823
[TBL] [Abstract][Full Text] [Related]
9. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
10. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
12. Chidamide works synergistically with Dasatinib by inducing cell-cycle arrest and apoptosis in acute myeloid leukemia cells.
Deng M; Xiao H; Peng H; Yuan H; Xiao X; Liu S
Mol Cell Biochem; 2023 Apr; 478(4):851-860. PubMed ID: 36107284
[TBL] [Abstract][Full Text] [Related]
13. [Establishment of the retrovirus-mediated murine model with MLL-AF9 leukemia].
Xu SM; Yang Y; Zhou M; Zhao XJ; Qin Y; Zhang PL; Yuan RF; Zhou JF; Fang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1126-32. PubMed ID: 24156419
[TBL] [Abstract][Full Text] [Related]
14. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
15. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
17. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
[TBL] [Abstract][Full Text] [Related]
18. Anti-Tumor and Immune Enhancing Activities of Rice Bran Gramisterol on Acute Myelogenous Leukemia.
Somintara S; Leardkamolkarn V; Suttiarporn P; Mahatheeranont S
PLoS One; 2016; 11(1):e0146869. PubMed ID: 26752299
[TBL] [Abstract][Full Text] [Related]
19. The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.
Macanas-Pirard P; Quezada T; Navarrete L; Broekhuizen R; Leisewitz A; Nervi B; Ramírez PA
PLoS One; 2017; 12(1):e0168888. PubMed ID: 28045930
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
